

Supplementary Table 6. Univariate and multivariate analyses in HER2-negative for prechemotherapy OS and PFS

Variable	OS						PFS						
	Univariate			Multivariate			Univariate			Multivariate			
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	
Age, yr													
< 65	1.00			1.00			1.00			1.00			
≥ 65	0.95	0.68–1.33	0.758	NS			0.91	0.64–1.28	0.572	NS			
Sex													
Female	1.00			1.00			1.00			1.00			
Male	0.99	0.71–1.38	0.943	NS			0.78	0.55–1.09	0.142	NS			
Detecting metastasis													
Recurrence	1.00			1.00			1.00			1.00			
Initial diagnosis	1.56	1.08–2.26	0.017	1.55	1.07–2.23	0.019	1.49	1.03–2.15	0.035	1.49	1.03–2.15	0.036	0.036
Histological type													
Differentiated	1.00			1.00			1.00			1.00			
Undifferentiated	1.67	1.17–2.38	0.004	1.73	1.21–2.46	0.003	1.43	1.00–2.03	0.048	NS			
Peritoneal carcinomatosis													
No	1.00			1.00			1.00			1.00			
Yes	1.37	1.00–1.90	0.054	NS			1.14	0.83–1.58	0.414	NS			
No. of metastatic organs													
1	1.00			1.00			1.00			1.00			
≥ 2	1.40	1.00–1.96	0.050	NS			1.38	0.98–1.94	0.068	NS			
First line chemotherapy													
Cisplatin based	1.00			1.00			1.00			1.00			
Non-cisplatin based	0.92	0.56–1.53	0.750	NS			0.73	0.43–1.23	0.238	NS			
Prechemotherapy NLR													
< 3.0	1.00			1.00			1.00			1.00			
≥ 3.0	1.35	1.11–1.64	0.003	1.83	1.28–2.61	0.001	1.37	1.13–1.66	0.002	1.63	1.14–2.32	0.007	0.007

There were 161 HER2-negative patients. Among them 109 patients were NLR ≤ 3.0 (102 patients died) and 52 patients were > 3.0 (48 patients died). HER, human epidermal growth factor receptor; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio.